These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 33431715)

  • 1. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.
    Huang SC; Su HJ; Kao JH; Tseng TC; Yang HC; Su TH; Chen PJ; Liu CJ
    Gut Liver; 2021 May; 15(3):451-458. PubMed ID: 33431715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
    Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
    World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease from clinical to pathological characteristics: a multi-center cross-sectional study in real world.
    Li Y; Dai C; Ruan Y; Yang H; Zeng H; Huang R; Wang J; Dai M; Hao J; Wang L; Li J; Yan X; Lu Z; Ji F
    Postgrad Med J; 2024 Apr; 100(1183):319-326. PubMed ID: 38272486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.
    McNally BB; Rangan P; Wijarnpreecha K; Fallon MB
    Dig Dis Sci; 2023 Sep; 68(9):3765-3773. PubMed ID: 37392337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
    Tsai PS; Cheng YM; Wang CC; Kao JH
    Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
    Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
    Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of clinical characteristics and risk factors of hepatic fibrosis in children with chronic hepatitis B combined with metabolic-related fatty liver disease].
    Li W; Jiang LN; Zhao BK; Liu HY; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jun; 31(6):601-607. PubMed ID: 37400384
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
    Johira Y; Nakahara T; Kinami T; Yamasaki S; Kosaka M; Shirane Y; Miura R; Murakami S; Yano S; Amioka K; Naruto K; Ando Y; Kosaka Y; Kodama K; Uchikawa S; Fujino H; Ono A; Murakami E; Okamoto W; Yamauchi M; Kawaoka T; Hayes CN; Tsuge M; Imamura M; Aikata H; Oka S
    BMC Gastroenterol; 2023 Jun; 23(1):222. PubMed ID: 37380950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
    Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
    Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics.
    Song BG; Kang TW; Sinn DH; Kim YY; Min JH; Hwang JA; Shin J
    Clin Imaging; 2024 Apr; 108():110097. PubMed ID: 38310832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China.
    Yang RX; Zou ZS; Zhong BH; Deng H; He FP; Shi JP; Zhao CY; Mi YQ; Zhou YJ; Di FS; Zheng RD; Du Q; Shang J; Popovic B; Chen J; Fan JG
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):426-432. PubMed ID: 34246549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].
    Shang MY; Chen YZ; Bao J; Tong YL
    Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):126-132. PubMed ID: 37137826
    [No Abstract]   [Full Text] [Related]  

  • 14. Overlapping group between non-alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research.
    Cheng YM; Hsieh TH; Wang CC; Kao JH
    JGH Open; 2024 Oct; 8(10):. PubMed ID: 39403113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
    Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
    Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome.
    Sinn DH; Kang D; Choi SC; Hong YS; Zhao D; Guallar E; Park Y; Cho J; Gwak GY
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1873-1880.e1. PubMed ID: 36152895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAFLD and risk of CKD.
    Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
    Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
    Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection.
    Wang MF; Wan B; Wu YL; Huang JF; Zhu YY; Li YB
    World J Gastroenterol; 2021 Jan; 27(4):336-344. PubMed ID: 33584066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.